NEUREN PHARMACEUT. ORDINARY (NEU) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASX
Google NewsWhy Neuren Pharmaceuticals (ASX:NEU) Is Up 6.3% After Record DAYBUE Royalties And Strong STIX Launch – And What's Next - simplywall.st
Why Neuren Pharmaceuticals (ASX:NEU) Is Up 6.3% After Record DAYBUE Royalties And Strong STIX Launch – And What's Next simplywall.st
Launch of Investor Hub to enhance shareholder engagement
other announcement
Motley FoolNeuren Pharmaceuticals Q1 2026: DAYBUE sales soar
Neuren Pharmaceuticals posted a strong Q1 2026, with DAYBUE net sales and royalty income both rising more than 20% year-on-year. The post Neuren Pharmaceuticals Q1 2026: DAYBUE sales soar appeared first on The Motley Fool Australia.
Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025
other announcement
DAYBUE STIX now broadly available in US for Rett syndrome
other announcement
Neuren Pharmaceuticals (ASX:NEU) Is Down 15.2% After 2025 Earnings Undershoot Expectations Has The Bull Case Changed? - simplywall.st
Neuren Pharmaceuticals (ASX:NEU) Is Down 15.2% After 2025 Earnings Undershoot Expectations Has The Bull Case Changed? simplywall.st
Change of Director's Interest Notice - J Basile
director_dealing announcement
Acadia confirms plan to request CHMP re-examination
other announcement
2025 royalty income A$65m, profit after tax A$30m
earnings announcement
Acadia reports DAYBUE net sales for 2025 and 2026 guidance
guidance announcement
Notification of Neuren investor webinar on 12 February 2026
other announcement
Neuren to commence new on-market share buy-back program
other announcement
Priority Review Voucher program reauthorized by US Congress
other announcement
Neuren receives US FDA meeting feeback for HIE and PTHS
other announcement
Acadia provides update on EU regulatory submission
other announcement
DAYBUE net sales projected to reach approx US$700m in 2028
other announcement
NNZ-2591 PMS Phase 2 trial published in Neurology Genetics
other announcement
Health Canada approves Clinical Trial Application for Koala
other announcement
FDA approves DAYBUE STIX (trofinetide), powder formulation
other announcement
One-month administrative delay to FDA meeting for HIE
other announcement
Record DAYBUE net sales of US$101.1 million in Q3 2025
other announcement
Fast Track granted by FDA for NNZ-2591 in Phelan-McDermid
other announcement
Neuren partners with Hope for HIE to support NNZ-2591
other announcement
H1 2025 profit after tax A$15m, up from A$8m in H1 2024
earnings announcement